Kelsey Goodwin
Stock Analyst at Guggenheim
(1.13)
# 3,478
Out of 4,784 analysts
17
Total ratings
41.67%
Success rate
-9.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Reiterates: Buy | n/a | $0.51 | - | 3 | Mar 28, 2025 | |
| GNLX Genelux | Initiates: Buy | $8 | $3.08 | +159.74% | 1 | Oct 29, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $99 → $105 | $73.05 | +43.74% | 2 | Sep 16, 2024 | |
| URGN UroGen Pharma | Initiates: Buy | $40 | $11.20 | +257.14% | 1 | Aug 22, 2024 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.26 | - | 1 | Jul 31, 2024 | |
| TSVT 2seventy bio | Downgrades: Neutral | n/a | $4.95 | - | 4 | Sep 13, 2023 | |
| ACLX Arcellx | Maintains: Buy | n/a | $67.96 | - | 3 | Jun 20, 2023 | |
| LEGN Legend Biotech | Initiates: Neutral | n/a | $35.06 | - | 1 | Oct 31, 2022 | |
| IOVA Iovance Biotherapeutics | Initiates: Neutral | n/a | $3.56 | - | 1 | Oct 31, 2022 |
Century Therapeutics
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.51
Upside: -
Genelux
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $3.08
Upside: +159.74%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $99 → $105
Current: $73.05
Upside: +43.74%
UroGen Pharma
Aug 22, 2024
Initiates: Buy
Price Target: $40
Current: $11.20
Upside: +257.14%
MacroGenics
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.26
Upside: -
2seventy bio
Sep 13, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.95
Upside: -
Arcellx
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $67.96
Upside: -
Legend Biotech
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $35.06
Upside: -
Iovance Biotherapeutics
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $3.56
Upside: -